Exelon vs Xcel Energy
EXC and XEL side by side, both in combination electric and gas, and other utility. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EXC and XEL compare
Exelon and Xcel Energy are about the same size, with market caps of $47.6B and $49.9B.
On earnings, Exelon is cheaper: it trades at 16.8× trailing earnings, against 18.6× for Xcel Energy.
Exelon grew revenue faster over the last twelve months (4.6% versus 4.5% for Xcel Energy).
Both pay dividends: Exelon yields 3.6% and Xcel Energy 2.9%.
Xcel Energy scores higher on the StockData Score (10 against 5 for Exelon), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EXC | XEL |
|---|---|---|
| Size and price | ||
| Market cap | $47.6B | $49.9B |
| Share price | $46.16 | $79.82 |
| Change, 1 year | −2.2% | 0.16% |
| Change, 5 years | −14.7% | 25.1% |
| Beta (5Y) | 0.23 | 0.32 |
| Employees | 21K | 12K |
| StockData Score | ||
| Total score | 5 | 10 (better) |
| Valuation score | 4 (better) | 2 |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 4 (better) |
| Health score | 0 | 0 |
| Dividend score | 1 | 3 (better) |
| Valuation | ||
| P/E | 16.8× (better) | 18.6× |
| P/S | 1.9× (better) | 3.4× |
| P/B | 1.6× (better) | 2.0× |
| EV/EBITDA | 11.0× (better) | 14.1× |
| PEG | – | 7.26 |
| FCF yield | −4.5% (better) | −15.3% |
| Fair value | $48.23 | $74.14 |
| Margin of safety | 4.3% (better) | −7.7% |
| Growth | ||
| Revenue growth (TTM) | 4.6% (better) | 4.5% |
| Revenue growth, 5Y average | 7.8% (better) | 4.9% |
| Net income growth (TTM) | – | 39.4% |
| EPS growth (TTM) | 1.9% | 30.8% (better) |
| EPS growth, 5Y average | – | 4.2% |
| Profitability | ||
| Operating margin | 21.0% | 21.7% (better) |
| Net margin | – | 17.9% |
| FCF margin | −8.7% (better) | −51.2% |
| Return on equity | – | 11.4% |
| Return on invested capital | 5.7% (better) | 5.5% |
| Financial health | ||
| Debt / equity | 1.73 | 1.59 (better) |
| Net debt / EBITDA | 5.63 (better) | 6.12 |
| Interest coverage | – | 1.9× |
| Current ratio | 0.94 (better) | 0.69 |
| Altman Z-score | 0.77 | 0.86 (better) |
| Piotroski F-score | – | 4 |
| Dividends and buybacks | ||
| Dividend yield | 3.6% (better) | 2.9% |
| Payout ratio | – | 52.4% |
| Years of dividend growth | 3 | 3 |
| Dividend growth, 5Y average | 0.90% | – |
| Buyback yield | −1.1% (better) | −6.1% |
| Shareholder yield | 2.5% (better) | −3.2% |
| Ownership | ||
| Held by institutions | 92.1% | 95.8% |
| Held by insiders | 0.08% | 0.23% |
| Insider net buying, 12 months | – | −$1.4M |
| Short interest, % of float | 3.3% | – |
Go deeper
- EXC stock overview
- EXC income statement
- EXC valuation and score
- XEL stock overview
- XEL income statement
- XEL valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.